Drug intelligence / Profile preview

SBT-104

Development stage: Preclinical
Lead developer: Singh Biotechnology
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

SBT-104 is a preclinical Singh Biotechnology single-domain antibody candidate directed against tumor necrosis factor alpha. The sponsor lists the program as being tested in vivo for rheumatoid arthritis, inflammatory bowel disease, and psoriasis. By inhibiting TNF-alpha, SBT-104 is intended to reduce TNF-driven inflammatory signaling relevant to autoimmune and inflammatory disorders. ([singhbiotechnology.com](https://singhbiotechnology.com/sbt104.html))

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on SBT-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-104.

Explore the full profile